Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
We examined the in vitro phenotypic and genotypic profiles of an extensively passaged human immunodeficiency virus type 1 clinical isolate which has been selected for lamivudine resistance, with an M184V mutation in a zidovudine-resistant genetic background, and then cultured with zidovudine alone. Our passaging strategy led to a decrease in lamivudine IC50 values, which were comparable to those prior to lamivudine exposure, and the genotypic restoration of the wild-type sequence at codon 184 of reverse transcriptase.
Rusconi
S
S
Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Italy. rusconi@imiucca.csi.unimi.it
De Pasquale
M P
MP
Milazzo
L
L
Kurtagic
S
S
Bulgheroni
E
E
Citterio
P
P
Galazzi
M
M
La Seta Catamancio
S
S
Galli
M
M
D019380:Anti-HIV Agents / Q000494:pharmacology*; D003062:Codon; D004351:Drug Resistance; D005838:Genotype; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D010641:Phenotype; D012194:RNA-Directed DNA Polymerase / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D014779:Virus Replication; D015215:Zidovudine / Q000494:pharmacology*
D019380:Anti-HIV Agents; D003062:Codon; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D012194:RNA-Directed DNA Polymerase